Table 1.
Disease characteristics at time of treatment
| Characteristics | Alternate | CAR T | P |
|---|---|---|---|
| Total, n | 146 | 69 | |
| Age | |||
| Median (range), y | 66 (27-91) | 63 (19-85) | .5 |
| >60 y, n (%) | 90 (62) | 43 (62) | >.9 |
| ECOG | .4 | ||
| 0-1, n (%) | 130 (92) | 60 (87) | |
| ≥2, n (%) | 12 (8.5) | 9 (13) | |
| Unknown, n | 4 | 0 | |
| Bulk >10 cm, n (%) | 23 (16) | 12 (17) | >.9 |
| Unknown, n | 3 | 0 | |
| Number of EN sites, n (%) | .5 | ||
| 0-1 | 97 (66) | 42 (61) | |
| >1 | 49 (34) | 27 (39) | |
| Elevated LDH, n (%) | 86 (66) | 31 (45) | .007 |
| Unknown, n | 15 | 0 | |
| Stage | >.9 | ||
| Limited, n (%) | 24 (16) | 11 (16) | |
| Advanced, n (%) | 122 (84) | 58 (84) | |
| BM involvement, n (%) | 5 (3.6) | 10 (21) | <.001 |
| Unknown, n | 9 | 22 | |
| Refractory disease | <.001 | ||
| No, n (%) | 31 (21) | 46 (67) | |
| Yes, n (%) | 114 (79) | 23 (33) | |
| Missing, n | 1 | 0 | |
| Prior AHCT, n (%) | 20 (14) | 14 (20) | .2 |
| Prior allogeneic-HCT, n (%) | 3 (2) | 4 (6) | .2 |
P values in bold are statistically significant.
BM, bone marrow; ECOG, Eastern cooperative oncology group; EN; extranodal.